EGFR and non-small cell lung carcinoma: Up to now, the advanced NSCLC patient with p.E746_S752delinsI still benefited from Icotinib treatment for a total of 19 months, with decreasing tumor burden and CEA level, which showed advanced LADC patients harboring EGFR p.E746_S752delinsI mutation could benefit from Icotinib.